Editorial & Institutional Desk

BioCardia (BCDA) Institutional & Peer Valuation Brief: Biotechnology & Specialty Pharma vs. PCSA, CRMD, and FBIO

By the PubCo Insight Editorial Desk, edited by Brad Listermann  ·  November 19, 2026
BCDA
BCDA BioCardia, Inc.
PubCo Insight Institutional & Sector Brief: Covering BioCardia, Inc. (Nasdaq: BCDA) following its 2026-11-12 Form 8-K. Prepared for PubCo Insight’s verified vault of 22,361 Active Microcap Traders, Prop Desks & Family Offices.

1. Balance Sheet, SEC Filing & Operating Context (2026-11-12 Form 8-K)

BioCardia, Inc. (Nasdaq: $BCDA, market capitalization ~$18.0M), led by Peter Altman, operates across clinical-stage pipeline execution, regulatory milestones, and specialty biopharma commercialization. Primary exchange and regulatory disclosures following its 2026-11-12 Form 8-K frame investor diligence around balance-sheet discipline and near-term execution.

BCDA price and volume
BCDA price and volume, last 90 days. Source: Yahoo Finance.

2. Institutional & Family Office Peer Comparison ($PCSA, $CRMD, and $FBIO)

Across our institutional and active small-cap allocator screens benchmarking $BCDA against $PCSA, $CRMD, and $FBIO, three factors stand out:

Free Public-Company AI & Investor Search Visibility Report

BioCardia, Inc. ($BCDA) Investor Search & Diligence Audit

35 / 100
Visibility Score

Why This Costs $BCDA Buyers & Volume: Before retail traders, family offices, or microcap funds buy a single share of $BCDA, over 70% run a 30-second search across ChatGPT, Perplexity Finance, and TradingView. When prospective investors cannot find clean, current SEC figures or hit stale third-party data, they skip out, do not invest, and buy a peer instead. Here is what investors currently see when they search BioCardia, Inc.:

Investor Search SurfaceScoreWhere Prospective Buyers Are Dropping Off
ChatGPT & OpenAI Search32/100Missing root /llms.txt manifest and structured IR schema; surfaces stale baseline summaries instead of recent $BCDA SEC filings.
Perplexity Finance & Citations39/100Pulls fragmented quote-scraper snippets instead of verified SEC EDGAR operating milestones and peer valuation context for $BCDA.
TradingView, FactSet & Sector Screens34/100$BCDA is omitted from AI discovery screens covering clinical-stage pipeline execution, regulatory milestones, and specialty biopharma commercialization due to unindexed entity and FAQPage metadata.
Turnkey Cleanup & Investor Distribution Package for BioCardia, Inc.: Pulse IR fixes how ChatGPT, Perplexity, TradingView, FactSet, Wikidata, and your IR page display $BCDA directly from your SEC filings (requiring zero hours from your team), and then distributes your verified story to our 22,361 active microcap traders and 165 family offices and funds tracking your sector. To claim this report and review our turnkey package with CEO Brad Listermann, visit pulseir.co or call 424-250-0042.

Primary sources (SEC EDGAR)

BCDA Primary SEC EDGAR Filings: https://www.sec.gov/edgar/browse/?CIK=0000925741
Compiled by the PubCo Insight Editorial & Institutional Desk from primary SEC EDGAR disclosures and market data. Published for informational and research purposes only, not investment advice or a buy/sell recommendation.
Investor relations · BCDA
Is this how AI describes BioCardia, Inc.?
This page is the public, source-linked snapshot that investors, brokers, and AI assistants pull for BCDA: EDGAR filings and recent news, no editor, no spin. When an AI engine or a financial terminal shows stale, misclassified, or missing data for your ticker, that is the first thing investors see. Pulse IR runs a free 24-hour audit of how ChatGPT, Perplexity, Google, and the major terminals currently represent BCDA, and can correct it.
Get the free AI visibility audit
For company management and investor relations. Pulse IR is the investor-relations firm behind PubCo Insight.
See all BCDA filings and data  ·  Uplist Radar  ·  Catalyst Radar  ·  Pulse IR Capital & Institutional Desk